ABBV vs JNJ: six-factor score, head to head
How AbbVie Inc. and Johnson & Johnsoncompare on Tapeline’s published six-factor composite score. Descriptive only — a rules-based reading of each name, not a recommendation.
Today, ABBV scores 72 and JNJ scores 74on Tapeline’s six-factor composite. JNJ carries the higher composite score today. Here’s how the six factors line up.
| Factor | ABBV | JNJ |
|---|---|---|
| Trend | 93 | 95 |
| Relative Strength | 57 | 68 |
| Fundamentals | 51 | 80 |
| Smart Money | 90 | 38 |
| Macro | 75 | 75 |
| Momentum | 50 | 75 |
smart-money factor below the score midpoint; positive trend factor reading; fundamentals factor on the upper side of its range.
momentum factor in the top band of its score. smart-money factor above the score midpoint and trend factor below the score midpoint.
The Tapeline Score is a descriptive, rules-based measure for information only — not investment advice or a recommendation to buy or sell. See the six-factor method and the public scorecard.
More comparisons
FAQ
- How do ABBV and JNJ compare on Tapeline?
- Tapeline scores ABBV 72/100 and JNJ 74/100 on its published six-factor composite (trend, relative strength, fundamentals, smart money, macro, momentum). The page breaks the two scores down factor by factor.
- Which has the higher Tapeline score, ABBV or JNJ?
- JNJ has the higher composite score today (72 vs 74). The score is a descriptive measure, not a recommendation — see the per-factor breakdown above.
- Is this investment advice?
- No. Tapeline publishes a descriptive, rules-based six-factor score for information only. It is not a recommendation to buy or sell, and every top pick is back-checked publicly at /scorecard.